Early hematopoietic recovery after single unit unrelated cord blood transplantation in adults supported by co-infusion of mobilized stem cells from a third party donor.

BACKGROUND AND OBJECTIVES Our objective was to improve the outcome of cord blood (CB) transplantation in adults, by overcoming the limitations imposed by the low number of stem cells present in CB units. DESIGN AND METHODS We combined single CB units and co-infusion of third party donor (TPD)-derived peripheral blood mobilized hematopoietic stem cells (MHSC) following myeloablative conditioning with reduced extra-hematologic toxicity. RESULTS Twenty-seven eligible patients with high-risk hematologic malignancies (age 16-60 years, median 29, weight 43-78 Kg, median 67) received CB units (median nucleated cell count 2.37x10(7)/Kg, median CD34+ cells 0.11x10(6)/Kg) co-infused with TPD-derived MHSC (2.30x10(6)/Kg CD34+ cells; <1x10(4)/Kg CD3+ cells). Neutrophil engraftment (>0.5x10(9)/L) occurred 10 days (9-36) post-transplant and was initially of TPD-origin in all patients except for four who received maternal MHSC, and then became of stable CB-origin. Median times to CB-derived neutrophil count >0.5x10(9)/L and full CB-chimerism were 22 and 55 days, respectively. The maximum cumulative incidence for engraftment, CB-engraftment and full CB-chimerism was 0.93 (95%CI: 0.83-1.00). The median time to reach unsupported platelet counts >20x10(9)/L was 33 days, with a maximum cumulative incidence of 0.74 (95%CI: 0.59-0.93). Transplant-related morbidity was associated primarily with non-neutropenic phase infections. Co-infusion of TPD-cells was well tolerated, with only 14.8% of recipients developing acute graft-versus-host disease (grade III-IV) and 20% developing a chronic (limited) form. The predicted 4-year overall survival was 69% for the whole group and 77% for the 23 patients receiving non-maternal TPD. INTERPRETATION AND CONCLUSIONS Our strategy offers prompt engraftment with a low rate of complications in a feasible alternative protocol that overcomes the current limitations of a single CB-transplant in adults.

[1]  Todd E DeFor,et al.  Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. , 2005, Blood.

[2]  J. Adamson,et al.  Outcomes among 562 recipients of placental-blood transplants from unrelated donors. , 1998, The New England journal of medicine.

[3]  J Wagner,et al.  Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. , 2002, Blood.

[4]  F. Derouin,et al.  Prophylaxis of toxoplasmosis infection with pyrimethamine/sulfadoxine (Fansidar) in bone marrow transplant recipients. , 1994, Bone marrow transplantation.

[5]  J. Wagner,et al.  Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. , 2003, Blood.

[6]  E. Shpall,et al.  Ex vivo expansion of umbilical cord blood. , 2005, Cytotherapy.

[7]  A. Zander,et al.  Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. , 2001, Blood.

[8]  J. Klein,et al.  Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. , 2000, The New England journal of medicine.

[9]  A. McWhinnie,et al.  Unrelated umbilical cord blood transplants in adults: Early recovery of neutrophils by supportive co-transplantation of a low number of highly purified peripheral blood CD34+ cells from an HLA-haploidentical donor. , 2003, Experimental hematology.

[10]  A. Little,et al.  Mutation detection and typing of polymorphic loci through double-strand conformation analysis , 1998, Nature Genetics.

[11]  P. Bolufer,et al.  Standardized, unrelated donor cord blood transplantation in adults with hematologic malignancies. , 2001, Blood.

[12]  T. Lion,et al.  Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification of short tandem repeat-markers , 2001, Leukemia.

[13]  N. Schmitz,et al.  Haploidentical ‘megadose’ stem cell transplantation in acute leukemia: recommendations for a protocol agreed upon at the Perugia and Chicago meetings , 2002, Leukemia.

[14]  I. Marugán,et al.  Engraftment kinetics of human CD34+ cells from cord blood and mobilized peripheral blood co-transplanted into NOD/SCID mice , 2005, Bone Marrow Transplantation.

[15]  J Crowley,et al.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.

[16]  P. Wernet,et al.  Cord blood comprises antigen-experienced T cells specific for maternal minor histocompatibility antigen HA-1. , 2005, Blood.

[17]  S. Asano,et al.  Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. , 2004, Blood.

[18]  S. Asano,et al.  Unrelated cord blood transplantation for adult patients with de novo acute myeloid leukemia. , 2004, Blood.

[19]  S. Asano,et al.  Unrelated cord blood transplantation for adult patients with advanced myelodysplastic syndrome. , 2003, Blood.

[20]  H. Einsele,et al.  Transplantation of a combination of CD133+ and CD34+ selected progenitor cells from alternative donors , 2004, British journal of haematology.

[21]  M. Sanz.  Cord-blood transplantation in patients with leukemia--a real alternative for adults. , 2004, The New England journal of medicine.

[22]  S. Chevret,et al.  Unrelated cord blood transplantation for childhood acute myeloid leukemia: a Eurocord Group analysis. , 2003, Blood.

[23]  C. Chastang,et al.  Outcome of cord-blood transplantation from related and unrelated donors , 1997 .